 Shares of Casi Pharmaceuticals Inc. CASI, 3.63 were up 10 in premarket trading on Friday after the company said China will allow a Phase 1 clinical trial evaluating a multiple myeloma drug developed by the privately held Cleave Therapeutics. The study is expected to start this year. 